Literature DB >> 31981791

Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities.

Nidhi Raval1, Akshant Kumawat1, Dnyaneshwar Kalyane1, Kiran Kalia1, Rakesh K Tekade2.   

Abstract

Diabetes and related complications are becoming a global encumbrance. Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD). The available therapeutic modalities related to DN do not treat DN at the molecular level, proposing further amendments in the management of DN based on the pathogenesis of DN. This manuscript discusses the concept and applications of nanomedicine for the treatment of DN that can improve renal targeting, retention and localization. This review also highlights the current issues related to targeting DN, challenges and allied opportunities toward the development of next-generation drugs and treatments for the management of DN.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID： 31981791     DOI： 10.1016/j.drudis.2020.01.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  7 in total

1.  Circ-AKT3 inhibits the accumulation of extracellular matrix of mesangial cells in diabetic nephropathy via modulating miR-296-3p/E-cadherin signals.

Authors:  Bo Tang; Weiliang Li; Ting-Ting Ji; Xiao-Ying Li; Xiaolei Qu; Linhong Feng; Shoujun Bai
Journal:  J Cell Mol Med       Date:  2020-06-28       Impact factor: 5.310

2.  Platycodin D regulates high glucose-induced ferroptosis of HK-2 cells through glutathione peroxidase 4 (GPX4).

Authors:  Jinzhong Huang; Gangyi Chen; Jilei Wang; Shibin Liu; Jing Su
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  Astragaloside IV Improves the Barrier Damage in Diabetic Glomerular Endothelial Cells Stimulated by High Glucose and High Insulin.

Authors:  Tingting Zhao; Jiaye Tian; Tiancheng Xu; Xi Zhang; Qian Xiang; Jianfeng Xiong; Dingkun Gui; Youhua Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-17       Impact factor: 2.629

4.  Paeoniflorin directly binds to TNFR1 to regulate podocyte necroptosis in diabetic kidney disease.

Authors:  Xian Wang; Xue-Qi Liu; Ling Jiang; Yue-Bo Huang; Han-Xu Zeng; Qi-Jin Zhu; Xiang-Ming Qi; Yong-Gui Wu
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 5.  Roles of Gut Microbial Metabolites in Diabetic Kidney Disease.

Authors:  Qing Fang; Na Liu; Binjie Zheng; Fei Guo; Xiangchang Zeng; Xinyi Huang; Dongsheng Ouyang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-20       Impact factor: 5.555

Review 6.  Circular RNA in renal diseases.

Authors:  Juan Jin; Haolu Sun; Chao Shi; Hui Yang; Yiwan Wu; Wanhai Li; Yu-Hang Dong; Liang Cai; Xiao-Ming Meng
Journal:  J Cell Mol Med       Date:  2020-04-25       Impact factor: 5.310

7.  Based on Network Pharmacology Tools to Investigate the Molecular Mechanism of Cordyceps sinensis on the Treatment of Diabetic Nephropathy.

Authors:  Yan Li; Lei Wang; Bojun Xu; Liangbin Zhao; Li Li; Keyang Xu; Anqi Tang; Shasha Zhou; Lu Song; Xiao Zhang; Huakui Zhan
Journal:  J Diabetes Res       Date:  2021-02-05       Impact factor: 4.011
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.